Literature DB >> 26449193

Response to: 'Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results'.

N Homer1, D S Grewal1, R G Mirza1, A T Lyon1, M K Gill1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26449193      PMCID： PMC5129812          DOI： 10.1038/eye.2015.191

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  1 in total

1.  Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results.

Authors:  N Homer; D S Grewal; R G Mirza; A T Lyon; M K Gill
Journal:  Eye (Lond)       Date:  2015-05-29       Impact factor: 3.775
  1 in total
  1 in total

Review 1.  "What should I inject next?" Challenging treatment decisions in the multiple anti-VEGF: a review of publications exploring anti-VEGF switching for nAMD.

Authors:  Joseph Pikkel; Shira Attas
Journal:  Int Ophthalmol       Date:  2017-08-29       Impact factor: 2.031
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.